检验医学 ›› 2022, Vol. 37 ›› Issue (4): 396-399.DOI: 10.3969/j.issn.1673-8640.2022.04.019
收稿日期:
2021-03-26
修回日期:
2021-07-23
出版日期:
2022-04-30
发布日期:
2022-06-07
通讯作者:
肖扬
作者简介:
肖 扬,E-mail: jdxiao111@163.com。Received:
2021-03-26
Revised:
2021-07-23
Online:
2022-04-30
Published:
2022-06-07
Contact:
XIAO Yang
摘要:
凝血因子(F)Ⅴ是调控并参与凝血初始反应的必需因子,对凝血酶的生成有极其重要的影响。最新研究发现FⅤ还具有抗凝特性。FⅤ基因(F5)的不同突变导致了出血或者血栓的形成。F5功能缺陷型突变常导致出血,如遗传性凝血因子Ⅴ缺陷症(FⅤD)患者多表现为不同程度的出血;但F5功能获得性突变则易形成血栓,如FⅤLeiden突变是高加索人群静脉血栓形成最常见的遗传危险因素。文章对FⅤ与出血和血栓相关性的研究进展进行综述。
中图分类号:
李可可, 肖扬. 凝血因子Ⅴ与出血和血栓的相关性研究进展[J]. 检验医学, 2022, 37(4): 396-399.
LI Keke, XIAO Yang. Research progress of coagulation factor Ⅴ and its association with hemorrhage and thrombosis[J]. Laboratory Medicine, 2022, 37(4): 396-399.
[1] |
PARABOSCHI E M, MENEGATTI M, PEYVANDI F, et al. Understanding the impact of aberrant splicing in coagulation factor V deficiency[J]. Int J Mol Sci, 2019, 20(4):910.
DOI URL |
[2] |
SRIDHARAN M, COON L M, CHEN D, et al. Factor V deficiency with a thrombotic clinical phenotype[J]. Semin Thromb Hemost, 2019, 45(1):108-112.
DOI URL |
[3] |
PARABOSCHI E M, MENEGATTI M, RIMOLDI V, et al. Profiling the mutational landscape of coagulation factor V deficiency[J]. Haematologica, 2020, 105(4):e180-e185.
DOI URL |
[4] | 丁红香, 苏看看, 胡立群, 等. 一个遗传性FⅤ缺陷症家系的表型与基因变异分析[J]. 中华医学遗传学杂志, 2019, 36(11):1100-1103. |
[5] |
BOUCHARD B A, ABDALLA S, TRACY P B. The factor V light chain mediates the binding and endocytosis of plasma-derived factor V by megakaryocytes[J]. J Thromb Haemost, 2013, 11(12):2181-2183.
DOI URL |
[6] |
DAHLBÄCK B. Novel insights into the regulation of coagulation by factor V isoforms,tissue factor pathway inhibitorα,and protein S[J]. J Thromb Haemost, 2017, 15(7):1241-1250.
DOI URL |
[7] |
KALAFATIS M, BECK D O, MANN K G. Structural requirements for expression of factor Va activity[J]. J Biol Chem, 2003, 278(35):33550-33561.
DOI URL |
[8] |
CAMIRE R M. A new look at blood coagulation factor V[J]. Curr Opin Hematol, 2011, 18(5):338-342.
DOI URL |
[9] |
DAHLBÄCK B. Pro- and anticoagulant properties of factor V in pathogenesis of thrombosis and bleeding disorders[J]. Int J Lab Hematol, 2016, 38(Suppl 1):4-11.
DOI URL |
[10] |
TABIBIAN S, SHIRAVAND Y, SHAMS M, et al. A comprehensive overview of coagulation factor V and congenital factor V deficiency[J]. Semin Thromb Hemost, 2019, 45(5):523-543.
DOI URL |
[11] |
MONKOVIĆ D D, TRACY P B. Functional characterization of human platelet-released factor V and its activation by factor Xa and thrombin[J]. J Biol Chem, 1990, 265(28):17132-17140.
DOI URL |
[12] |
GREMMEL T, FRELINGER A L 3rd, MICHELSON A D. Platelet physiology[J]. Semin Thromb Hemost, 2016, 42(3):191-204.
DOI URL |
[13] |
HOSSEINZADEGAN H, TAFTI D K. Modeling thrombus formation and growth[J]. Biotechnol Bioeng, 2017, 114(10):2154-2172.
DOI URL |
[14] |
CAMIRE R M, KALAFATIS M, CUSHMAN M, et al. The mechanism of inactivation of human platelet factor Va from normal and activated protein C-resistant individuals[J]. J Biol Chem, 1995, 270(35):20794-20800.
DOI URL |
[15] |
ARIENS R, BECATTINI C, BENDER M, et al. Illustrated state-of-the-art capsules of the ISTH 2020 congress[J]. Res Pract Thromb Haemost, 2020, 4(5):680-713.
DOI URL |
[16] |
CASTOLDI E, ROSING J. APC resistance:biological basis and acquired influences[J]. J Thromb Haemost, 2010, 8(3):445-453.
DOI URL |
[17] |
DUGA S, ASSELTA R, TENCHINI M L. Coagulation factor V[J]. Int J Biochem Cell Biol, 2004, 36(8):1393-1399.
DOI URL |
[18] |
SANTAMARIA S, REGLIŃSKA-MATVEYEV N, GIERULA M, et al. Factor V has an anticoagulant cofactor activity that targets the early phase of coagulation[J]. J Biol Chem, 2017, 292(22):9335-9344.
DOI URL |
[19] | OWREN P A. New factors concerned in the coagulation of blood[J]. Bulletin Schweiz Akad Med Wiss, 1947, 3(23):163-177. |
[20] |
PARK Y H, LIM J H, YI H G, et al. Factor V deficiency in Korean patients:clinical and laboratory features,treatment,and outcome[J]. J Korean Med Sci, 2016, 31(2):208-213.
DOI URL |
[21] | PARK C H, PARK M S, LEE K O, et al. Congenital factor V deficiency from compound heterozygous mutations with a novel variant c.2426del(p.Pro809Hisfs*2) in the F5 gene:a case report[J]. Medicine(Baltimore), 2020, 99(5):e18947. |
[22] | ASSELTA R, TENCHINI M L, DUGA S. Inherited defects of coagulation factor V:the hemorrhagic side[J]. J Thromb Haemost, 2006, 4(1):26-34. |
[23] | MONTEFUSCO M C, DUGA S, ASSELTA R, et al. A novel two base pair deletion in the factor V gene associated with severe factor V deficiency[J]. Br J haematol, 2000, 111(4):1240-1246. |
[24] | BORHANY M, RANC A, FRETIGNY M, et al. Molecular analysis of eight severe FV-deficient patients in Pakistan:a large series of homozygous for frameshift mutations[J]. Haemophilia, 2019, 25(4):e278-e281. |
[25] |
CASTOLDI E, DUCKERS C, RADU C, et al. Homozygous F5 deep-intronic splicing mutation resulting in severe factor V deficiency and undetectable thrombin generation in platelet-rich plasma[J]. J Thromb Haemost, 2011, 9(5):959-968.
DOI URL |
[26] |
NUZZO F, BESHLAWI I, WALI Y, et al. High incidence of intracranial bleeding in factor V-deficient patients with homozygous F5 splicing mutations[J]. Br J Haematol, 2017, 179(1):163-166.
DOI URL |
[27] | 傅卫军, 侯健, 王东星, 等. 凝血因子Ⅴ基因的一种新突变的发现与确证[J]. 中华医学杂志, 2003, 83(1):24-26. |
[28] |
LAK M, SHARIFIAN R, PEYVANDI F, et al. Symptoms of inherited factor V deficiency in 35 Iranian patients[J]. Br J Haematol, 1998, 103(4):1067-1069.
DOI URL |
[29] | DUCKERS C, SIMIONI P, SPIEZIA L, et al. Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency[J]. Blood, 2008, 112(9):3615-3623. |
[30] | PARUNOV L A, SUROV S S, CHATTOPADHYAY M, et al. Thrombin generation assay modifications needed for its application to monitoring of replacement therapy for haemophilia[J]. Haemophilia, 2021, 27(1):e129-e132. |
[31] |
BILLOIR P, FEUGRAY G, CHRÉTIEN M H, et al. Thrombin generation assay is a useful pre-operative tool to predict non-bleeding risk in a patient with mild factor V deficiency[J]. Transfus Med, 2020, 30(5):408-409.
DOI URL |
[32] |
DUCKERS C, SIMIONI P, SPIEZIA L, et al. Residual platelet factor V ensures thrombin generation in patients with severe congenital factor V deficiency and mild bleeding symptoms[J]. Blood, 2010, 115(4):879-886.
DOI URL |
[33] |
VAN DOORN P, ROSING J, DUCKERS C, et al. Factor V has anticoagulant activity in plasma in the presence of TFPIα:difference between FV1 and FV2[J]. Thromb Haemost, 2018, 118(7):1194-1202.
DOI URL |
[34] |
CHOWDARY P. Anti-tissue factor pathway inhibitor(TFPI) therapy:a novel approach to the treatment of haemophilia[J]. Int J Hematol, 2020, 111(1):42-50.
DOI URL |
[35] |
GUPTA G K, HENDRICKSON J E, BAHEL P, et al. Factor V activity in apheresis platelets:implications for management of FV deficiency[J]. Transfusion, 2021, 61(2):405-409.
DOI URL |
[36] |
DRZYMALSKI D M, ELSAYES A H, WARD K R, et al. Platelet transfusion as treatment for factor V deficiency in the parturient:a case report[J]. Transfusion, 2019, 59(7):2234-2237.
DOI URL |
[37] |
THALJI N, CAMIRE R M. Parahemophilia:new insights into factor V deficiency[J]. Semin Thromb Hemost, 2013, 39(6):607-612.
DOI URL |
[38] |
BULATO C, NOVEMBRINO C, ANZOLETTI M B, et al. "In vitro" correction of the severe factor V deficiency-related coagulopathy by a novel plasma-derived factor V concentrate[J]. Haemophilia, 2018, 24(4):648-656.
DOI URL |
[39] |
NAIR P M, RENDO M J, REDDOCH-CARDENAS K M, et al. Recent advances in use of fresh frozen plasma,cryoprecipitate,immunoglobulins,and clotting factors for transfusion support in patients with hematologic disease[J]. Semin Hematol, 2020, 57(2):73-82.
DOI URL |
[40] |
NAKAMURA T, MORISHIGE S, OZAWA H, et al. Successful correction of factor V deficiency of patient-derived iPSCs by CRISPR/Cas9-mediated gene editing[J]. Haemophilia, 2020, 26(5):826-833.
DOI URL |
[41] | VOS H L. Inherited defects of coagulation factor V:the thrombotic side[J]. J Thromb Haemost, 2006, 4(1):35-40. |
[42] | APPLEGATE J S, GRONEFELD D. Factor V leiden[J]. Radiol Technol, 2019, 90(3):259-273. |
[43] |
WILLIAMSON D, BROWN K, LUDDINGTON R, et al. Factor V Cambridge:a new mutation(Arg306→Thr) associated with resistance to activated protein C[J]. Blood, 1998, 91(4):1140-1144.
DOI URL |
[44] |
PEZESHKPOOR B, CASTOLDI E, MAHLER A, et al. Identification and functional characterization of a novel F5 mutation(Ala512Val,FVBonn ) associated with activated protein C resistance[J]. J Thromb Haemost, 2016, 14(7):1353-1363.
DOI URL |
[45] |
NOGAMI K, SHINOZAWA K, OGIWARA K, et al. Novel FV mutation(W1920R,FVNara) associated with serious deep vein thrombosis and more potent APC resistance relative to FVLeiden[J]. Blood, 2014, 123(15):2420-2428.
DOI URL |
[46] | DORGALALEH A, DABBAGH A, TABIBIAN S, et al. Persistent hiccups in a patient with mild congenital factor V deficiency and COVID-19;clinical and laboratory finding of a rare bleeding disorder[J]. Int J Lab Hematol, 2021, 43(2):e87-e88. |
[1] | 缪星国, 叶慧, 苏菲菲. GeneXpert MTB/RIF检出量与结核分枝杆菌培养和利福平表型耐药的关系[J]. 检验医学, 2023, 38(9): 874-877. |
[2] | 蔡春艳, 上官华坤, 吴文涌, 张莹, 袁欣, 陈瑞敏. HUWE1基因变异致X连锁智力障碍临床表型和遗传学分析[J]. 检验医学, 2023, 38(2): 117-123. |
[3] | 王维维, 章黎华, 姜文理, 何珂骏, 万江波, 沈立松. CD5+急性B淋巴细胞白血病和急性髓系白血病各1例报道[J]. 检验医学, 2023, 38(2): 196-199. |
[4] | 茹浩浩, 陈连勇, 杨星, 陈涛, 闫双群, 许琳. Xpert MTB/RIF与结核分枝杆菌利福平耐药表型检测一致性分析[J]. 检验医学, 2023, 38(11): 1032-1035. |
[5] | 朱丰村, 曾云祥, 金晓立, 曾添, 黄天鹏, 林枝, 周林双. 204株碳青霉烯类耐药肠杆菌目细菌耐药性分析[J]. 检验医学, 2023, 38(1): 60-65. |
[6] | 方颖慧, 王卫国, 张华, 古艳, 郑芳, 李丽萍. 母细胞性浆细胞样树突状细胞肿瘤临床与实验室特点分析[J]. 检验医学, 2022, 37(5): 433-437. |
[7] | 王婧婧, 吴林清, 陈如寿, 王玉丰. 耐万古霉素肠球菌耐药基因、转座子结构和多位点序列分析[J]. 检验医学, 2021, 36(9): 891-895. |
[8] | 方忠俊, 季蔚青, 张婧娴, 吴金涛, 吴伟华, 蒋莹, 韩振格, 何东仪, 边艳琴, 沈瑜, 肖涟波, 谢东浩, 孙阳. 痛风性关节炎患者HLA-B*5801基因型携带率及相关实验室指标分析[J]. 检验医学, 2021, 36(9): 896-900. |
[9] | 焦瑞宝, 唐吉斌, 周佳丽, 朱娟娟, 陈继中. GPⅠa基因G873A、C807T位点在心脑血管疾病和糖尿病患者中的多态性分布[J]. 检验医学, 2021, 36(6): 581-585. |
[10] | 顾玉微, 王成云, 顾萍, 潘秋辉, 王静, 陈广洁. ABO等位基因调控区突变致抗原弱表达原因分析[J]. 检验医学, 2021, 36(6): 637-641. |
[11] | 李育敏, 蔡钦泉, 覃俊龙, 金潇, 陈亚琼, 莫云均, 李悦, 张秀明. 3种β缺失型地中海贫血基因型与表型分析[J]. 检验医学, 2021, 36(6): 642-645. |
[12] | 郁婷婷, 傅启华. 罕见病诊治思考与展望[J]. 检验医学, 2021, 36(2): 119-121. |
[13] | 毕晓洁, 黄道超, 金先富, 姜俊宇, 苏正仙, 陈超超, 沈波. 1个复合杂合突变导致的凝血因子Ⅺ缺陷症家系表型及基因型分析[J]. 检验医学, 2020, 35(10): 1036-1039. |
[14] | 李育敏, 蔡钦泉, 金潇, 覃俊龙, 陈亚琼, 莫云均, 李瑞, 张秀明. 成人及新生儿血红蛋白NewYork的血液学特征分析[J]. 检验医学, 2020, 35(10): 1049-1052. |
[15] | 李育敏, 张水兰, 阚丽娟, 张兵, 汤花梅, 李瑞, 张秀明. 罕见地中海贫血基因变异的分子特征与表型[J]. 检验医学, 2019, 34(7): 613-616. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||